Contemporary Management of Risk Factors in Coronary Artery Disease (Part 2)

Dimitris      Tousoulis; Panagiotis      Theofilis

doi:10.2174/138161282935231207112504

[1]
Siasos G, Tsigkou V, Bletsa E, et al. Antithrombotic treatment in coronary artery disease. Curr Pharm Des  2023; 29(35): 2764-79.

[2]
Tsioufis PA, Theofilis P, Vlachakis PK, et al. Novel invasive methods as the third pillar for the treatment of essential uncontrolled hypertension. Curr Pharm Des  2023; 29(35): 2780-6.

[3]
Sagris M, Theofilis P, Papanikolaou A, et al. Direct oral anticoagulants use in patients with stable coronary artery disease, acute coronary syndrome or undergoing percutaneous coronary intervention. Curr Pharm Des  2023; 29(35): 2787-94.

[4]
Papastamos C, Antonopoulos AS, Simantiris S, et al. Stem cell-based therapies in cardiovascular diseases: From pathophysiology to clinical outcomes. Curr Pharm Des  2023; 29(35): 2795-801.

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Contemporary Management of Risk Factors in Coronary Artery Disease (Part 2)

Volume: 29 Issue: 35

Author(s): Dimitris Tousoulis and Panagiotis Theofilis

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Tousoulis Dimitris and Theofilis Panagiotis, Contemporary Management of Risk Factors in Coronary Artery Disease (Part 2), Current Pharmaceutical Design 2023; 29 (35) . https://dx.doi.org/10.2174/138161282935231207112504

DOI https://dx.doi.org/10.2174/138161282935231207112504	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 30 July, 2024

"Tuberculosis Prevention, Diagnosis and Drug Discovery"

The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more

Guest Editor(s): Dr. M Pinheiro

Submission closes on : 03 December, 2024

Blood-based biomarkers in large-scale screening for neurodegenerative diseases

Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more

Guest Editor(s): Dr. Carlo Cervellati

Submission closes on : 18 September, 2024

Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more

Guest Editor(s): Dr. Sidharth Mehan

Submission closes on : 03 December, 2024

Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine

Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

Guest Editor(s): Dr. Ali Yadollahpour,